Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic of...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Lysogenic Cycle of Bacteriophages00:43

Lysogenic Cycle of Bacteriophages

In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prion-like transmission and propagation of human β-amyloid to the bank vole rodent model.

Acta neuropathologica·2026
Same author

Prevalence of Lewy body pathology and phenotypic associations in patients with mild cognitive impairment: Evidence from the Interceptor study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Mild cognitive impairment-to-Alzheimer's dementia progression risk: the contribution of the Interceptor project.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

D178N prion protein mutation endows RML prions with new strain properties that do not mimic human genetic prion diseases.

Acta neuropathologica·2026
Same author

Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.

Brain sciences·2026
Same author

Plasma extracellular vesicles and phosphorylated tau 181 as early biomarkers of cognitive impairment in Alzheimer's dementia.

Alzheimer's research & therapy·2026

Related Experiment Video

Updated: Jun 25, 2026

Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

Tetracyclines and prion infectivity.

Gianluigi Forloni1, Mario Salmona, Gabriella Marcon

  • 1Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy. forloni@marionegri.it

Infectious Disorders Drug Targets
|February 10, 2009
PubMed
Summary

Tetracyclines, like doxycycline, show promise in treating prion diseases by destabilizing harmful protein aggregates. These antibiotics are being explored clinically for transmissible spongiform encephalopathies (TSEs).

More Related Videos

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
12:57

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
11:41

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

Published on: March 10, 2015

Related Experiment Videos

Last Updated: Jun 25, 2026

Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
12:57

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans

Published on: January 8, 2015

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
11:41

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

Published on: March 10, 2015

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Polycyclic compounds, including anthracyclines, have demonstrated potential anti-prion activity.
  • Idoxorubicin showed reduced infectivity in experimental scrapie models.
  • Tetracyclines, chemically related to anthracyclines, are safer antibiotics with therapeutic potential for prion diseases.

Purpose of the Study:

  • To evaluate tetracyclines as a therapeutic tool for transmissible spongiform encephalopathies (TSEs).
  • To investigate the mechanism of action of tetracyclines against prion protein (PrP) aggregates.
  • To assess the efficacy of tetracyclines in preclinical and clinical settings for prion diseases.

Main Methods:

  • In vitro studies using synthetic PrP peptides and pathological PrP (PrPsc) aggregates.
  • Cellular and animal models of TSEs.
  • Clinical investigations of tetracycline treatment for prion diseases.

Main Results:

  • Tetracyclines, particularly doxycycline and minocycline, interact with PrP aggregates and destabilize amyloid fibrils.
  • Reduced resistance of PrP aggregates to proteinase K digestion was observed.
  • Inhibition of protein misfolding and reduction of infectivity in experimental scrapie models were demonstrated.
  • Curative effects were noted after both peripheral and intracerebral doxycycline administration.
  • Positive results were obtained when testing tetracyclines' anti-amyloidogenic activity in other forms of amyloidosis.

Conclusions:

  • Tetracyclines are effective therapeutic agents against prion diseases by targeting PrP misfolding and aggregation.
  • Doxycycline and minocycline show significant potential for treating TSEs and other amyloidogenic diseases.
  • Further clinical investigation of tetracyclines for prion diseases is warranted.